MOMO'S BREAKOUT BOARD

[dirkv]

APREA THERAPEUTICS INC APRE: 0,48
52w: 0.3310 - 4.7

https://ir.aprea.com/static-files/30f4a16e-335b-4fa5-83d1-592b0aade43f

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aprea Therapeutics (APRE - Research Report) and set a price target of $3.00.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing and commercializing novel cancer therapeutics that reactivate mutant protein 53 (p53) tumor suppressor protein. The Company's lead product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes, or myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The Company's APR-548 is a second generation p53 reactivator that is a unique analog of eprenetapopt and therefore a pro-drug of MQ. APR-548 exhibits high oral bioavailability in preclinical testing and is being developed in an oral dosage form. The Company has initiated a Phase I clinical trial testing APR-548 in relapsed/refractory MDS and AML. Its solid tumor program includes its clinical trial evaluating eprenetapopt with anti-PD-1 therapy in advanced solid tumors.

Total Cash (mrq) 33.11M
Total Cash Per Share (mrq) 0.62
Total Debt (mrq) 110.55k
Shares Outstanding 53M
% Held by Insiders 24.17%


Sep 30, 2022 0.8380
Jun 30, 2022 1.2900
Apr 30, 2022 1.5500
Mar 31, 2022 2.0400
Jan 01, 2022 3.2100
Dec 01, 2021 4.7000
Sep 30, 2021 5.6700
May 31, 2021 7.8000
Dec 01, 2020 30.9910